This study will evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY conjugate vaccine

• Experimental: Children 2-5 years of age, 1 dose of MenACWY
• Active Comparator: Children 2-5 years of age, 1 dose of MenACWY
• Experimental: Children 6-10 years of age, 1 dose of MenACWY
• Active Comparator: Children 6-10 years of age, 1 dose of MenACWY
• Experimental: Children 2-5 years of age, Men ACWY Day 1 and Men ACWY Day 61

Inclusion Criteria:

• healthy 2-10 years of age children, inclusive and for whom, after the nature of the study has been explained, the parent or legal guardian has provided written informed consent
• who are available for all visits and telephone calls scheduled for the study
• who are up-to-date with age-appropriate routine childhood vaccinations

Exclusion Criteria:

• whose parent or legal guardian is unwilling or unable to give written informed consent
• who had a previous or suspected disease caused by N. meningitidis;
• who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
• who have received any investigational agents or vaccines within 90 days prior to enrollment
• who have any serious acute, chronic or progressive disease
• who have epilepsy or any progressive neurological disease or history of Guillain Barré Syndrome
• who have a history of anaphylaxis, serious vaccine reactions
• who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from
• who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
• who have Down's syndrome or other known cytogenic disorders